External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home APVRS 2024
Roche and Genentech at

APVRS 2024

November 22 - November 24
Singapore, Singapore
2024.apvrs.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
03:12 AM
Duration 6mins Rapid Fire 2 - Intraocular Inflammation, Uveitis & Scleritis
Intravitreal Interleukin-6 Inhibition With Vamikibart in Uveitic Macular Edema: Final Results From the Phase 1 DOVETAIL Study
Agrawal R, Steeples L, Elze M, Macgregor L, Stoilov I, Silverman D, Mesquida M, Haskova Z
Ophthalmology | Uveitic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:24 AM
Duration 6mins Rapid Fire 2 - Intraocular Inflammation, Uveitis & Scleritis
IL-6 Inhibition with Vamikibart in Patients with Uveitic Macular Edema: Study Design of the Phase 3 MEERKAT and SANDCAT trials
Hwang Y, Steeples L, Elze M, Macgregor L, Silverman D, Haskova Z
Ophthalmology | Uveitic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:30 AM
Duration 5mins Rapid Fire 3 - Retina (Medical) (1)
Patient Preference for the Port Delivery System With Ranibizumab (PDS) vs Intravitreal Injections: 1-Year Results From the Phase 3 Pagoda Trial in Patients With Diabetic Macular Edema (DME)
Koh A, Chang M, Marcus D, Baldonado K, Daly A, Tian K
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:35 AM
Duration 5mins Rapid Fire 3 - Retina (Medical) (1)
Efficacy, Durability and Safety of Faricimab▼ in DME: 2-Year Results from China Subpopulation of Phase 3 RHINE Trial
Sun X, Chen Q, Shi Y
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:45 AM
Duration 5mins Rapid Fire 3 - Retina (Medical) (1)
Port Delivery System With Ranibizumab for Continuous Treatment in Diabetic Retinopathy: First Readout of 2-Year Data From the Phase 3 Pavilion Trial
Lai T, Chang M, Awh C, Khanani A, Tian K, Latkany P
Ophthalmology | Diabetic Retinopathy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:10 AM
Duration 5mins Rapid Fire 3 - Retina (Medical) (1)
Faricimab▼ in Diabetic Macular Edema: Results from the RHONE-X Long-Term Extension Trial
Chang A, Sim D, Khanani A, Kotak A, Tang Y, Kotecha A
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:05 AM
Duration 5mins Rapid Fire 5 - Retina (Medical) (2)
Response of Large or Serous Pigment Epithelial Detachment to Faricimab▼ versus Aflibercept in Patients with Neovascular Age-related Macular Degeneration: A Subgroup Analysis from TENAYA and LUCERNE
Hsieh Y, Harrell E, Margaron P, Patel S, Yang M, Lai T
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:15 AM
Duration 5mins Rapid Fire 5 - Retina (Medical) (2)
Real-World Effectiveness of Faricimab▼ in Patients with Diabetic Macular Edema: 12-Month Outcomes from FARETINA-DME and FARWIDE-DME Studies
Szeto S, Singh R, Borkar D, Tabano D, Peto T, Dayal P
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:35 AM
Duration 5mins Rapid Fire 5 - Retina (Medical) (2)
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
Cheung G, Iida T, Bai R, Margaron P, Nguyen Duc A, Lai T
Ophthalmology | Polypoidal Choroidal Vasculopathy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:40 AM
Duration 5mins Rapid Fire 5 - Retina (Medical) (2)
Global Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema From a Multi-Country Prospective Non-Interventional Study: The VOYAGER Study
Koh A, Bailey C, Chi G, Shi B, Uschner D, Guymer R
Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:10 AM
Duration 5mins Rapid Fire 5 - Retina (Medical) (2)
Real-World Effectiveness of Faricimab▼ in Patients with Neovascular Age-Related Macular Degeneration: 12-Month Outcomes from the FARETINA-nAMD and FARWIDE-nAMD Studies
Lin T, Singh R, Borkar D, Tabano D, Talks J, Dayal P
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.